53 articles for JC Medina
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
Amgen
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
Amgen
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
Amgen
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
Amgen
Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP.
Amgen
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Amgen
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
Amgen
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.
Amgen
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
Amgen
Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
Amgen
Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
Amgen
Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.
Amgen
Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
Amgen
Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
Amgen
Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Amgen
Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
Amgen
Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists.
Amgen
Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism.
Amgen
Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity.
Amgen
Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.
Amgen
Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors.
Amgen
Novel Series of Potent Glucokinase Activators Leading to the Discovery of AM-2394.
Amgen
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties.
Amgen
Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).
Oric Pharmaceuticals
Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.
TBA
Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).
Oric Pharmaceuticals
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
Merck Sharp & Dohme
Structure of REV-ERBß ligand-binding domain bound to a porphyrin antagonist.
The Scripps Research Institute
The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
Harvard Neurodiscovery Center
Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.
University of Otago Christchurch